Marizev (omarigliptin; Merck & Co) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class. DPP-IV is an enzyme responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1 (GLP-1), which is released postprandially from the gut. Inhibition of DPP-IV augments the amount of active GLP-1, which in turn triggers increased insulin secretion from the pancreas in a glucose-dependent manner and suppresses the release of glucagon, resulting in lowered blood glucose levels.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Marizev : Diabetes type 2
LIST OF FIGURES
9 Figure 1: Marizev for type 2 diabetes – SWOT analysis
10 Figure 2: Datamonitor Healthcare drug assessment of Marizev
11 Figure 3: Datamonitor Healthcare drug assessment scorecard for Marizev compared to Januvia
13 Figure 4: Marizev sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES
4 Table 1: Marizev drug profile
6 Table 2: Marizev pivotal trial data in type 2 diabetes
8 Table 3: Marizev ongoing late-phase clinical trials in type 2 diabetes
14 Table 4: Marizev sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.